Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 6/20 | 0.65 |
| ▸ | KCNJ1 | P48048 | 9/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366960 | 1.00 | PRF1 (0.65) | PRF1KCNJ1KCNH2MAPTLMNA | |
| Tetrahydrofuran SCHEMBL22089885 | 0.91 | PRF1 (0.56) | PRF1KCNJ1KCNH2MAPTLMNA | |
| Toluene SCHEMBL28417431 | 0.89 | PRF1 (0.55) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL148003 | 0.86 | PRF1 (0.54) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL28914301 | 0.83 | PRF1 (0.59) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL29933676 | 0.83 | PRF1 (0.59) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL22089880 | 0.83 | PRF1 (0.49) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL24442281 | 0.82 | MAPT (0.56) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL13454843 | 0.79 | GRM5 (0.59) | PRF1MAPTLMNAGAAMAOA | |
| SCHEMBL31503953 | 0.79 | PRF1 (0.43) | PRF1KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570901-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | Buddhist Tzu Chi Medical Foundation (TW) | 2025-06-18 | — | — | EP | claimed |
| CN-120137900-A | Method for selectively removing undifferentiated pluripotent stem cells | 佛教慈济医疗财团法人 | 2025-06-13 | — | — | CN | claimed |
| US-20250188411-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-06-12 | — | — | US | claimed |
| CN-119775242-A | Method for synthesizing 5-cyanophthalide | 内蒙古源宏精细化工有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-11845710-B2 | Method for continuously preparing citalopram diol | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2023-12-19 | — | — | US | claimed |
| CN-113329994-B | Method for continuously preparing 5-cyanodiol | 浙江华海药业股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-111302971-B | Method for continuously preparing 5-cyanodiol | 上海奥博生物医药股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| EP-3896057-B1 | METHOD FOR CONTINUOUSLY PREPARING CITALOPRAM DIOL | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-05-31 | — | — | EP | claimed |
| CN-112409212-B | Preparation method of citalopram diol intermediate hydrobromide, citalopram diol intermediate hydrobromide and citalopram | 四川新迪医药化工有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114761004-A | Process for the preparation of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide | 细胞基因公司 | 2022-07-15 | — | — | CN | claimed |
| US-20020019546-A1 | Method for the preparation of 5-cyanophthalide | H. LUNDBECK A/S (DK) | 2002-02-14 | — | — | US | claimed |
| EP-1150966-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. Lundbeck A/S (DK) | 2001-11-07 | — | — | EP | claimed |
| EP-1140886-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2001051477-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2001-07-19 | — | — | WO | claimed |
| WO-2000044738-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2000-08-03 | — | — | WO | claimed |
| WO-2000039112-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2000-07-06 | — | — | WO | claimed |
| WO-2000012044-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-09 | — | — | WO | claimed |
| EP-0171943-B1 | NOVEL INTERMEDIATE AND METHOD FOR ITS PREPARATION | H. LUNDBECK A/S (DK) | 1988-11-17 | — | — | EP | claimed |
| US-4650884-A | 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (racemic citalopram diol) as intermediate to citalopram | H. LUNDBECK A/S (DK) | 1987-03-17 | — | — | US | claimed |
| EP-0171943-A1 | Novel intermediate and method for its preparation | H. LUNDBECK A/S (DK) | 1986-02-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845710-B2 | Method for continuously preparing citalopram diol | GRHPR, TPH2, SLC6A4 | PRF1 4548/4885KCNJ1 4346/4885KCNH2 3743/4885 |
| US-20020019546-A1 | Method for the preparation of 5-cyanophthalide | SLC6A4, TPH1, CPS1 | PRF1 3419/4885KCNJ1 837/4885KCNH2 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.